EPS Creative Health to Acquire 16.23% Stake in China Genetic for HK$43 Million

EPS Creative Health Technology Group Limited ( (HK:3860) ) has provided an announcement.

EPS Creative Health Technology Group Limited has agreed to acquire 16.23% of the issued share capital of China Genetic Limited for a total cash consideration of HK$43 million. The deal was reached with a vendor controlled by two existing directors, meaning the investment will be treated as an interest in an associate in the group’s consolidated financial statements.

Because the vendor is a connected person and the deal size exceeds key thresholds, the acquisition is classified as a discloseable and connected transaction under Hong Kong listing rules, triggering notification, announcement and independent shareholders’ approval requirements. The consideration, benchmarked against an independent valuation of HK$43.7 million, will be funded through internal resources and potentially future fundraising, signaling a targeted expansion of the group’s footprint in related healthcare assets.

The most recent analyst rating on (HK:3860) stock is a Buy with a HK$0.72 price target. To see the full list of analyst forecasts on EPS Creative Health Technology Group Limited stock, see the HK:3860 Stock Forecast page.

More about EPS Creative Health Technology Group Limited

EPS Creative Health Technology Group Limited is a Hong Kong-listed company that invests in and operates businesses within the healthcare and health technology sectors. The group focuses on expanding its portfolio through strategic equity stakes in related companies, aiming to strengthen its position and influence in the broader health and wellness market.

Average Trading Volume: 234,696

Technical Sentiment Signal: Buy

Current Market Cap: HK$355.1M

Find detailed analytics on 3860 stock on TipRanks’ Stock Analysis page.